Alliancebernstein L.P. Arcus Biosciences, Inc. Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 1,300,954 shares of RCUS stock, worth $20.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,300,954

Previous 1,260,782 3.19%

Holding current value

$20.7 Million

Previous $19.2 Million 3.59%

% of portfolio

0.01%

Previous 0.01%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$13.69 - $18.01 $549,954 - $723,497	40,172 Added 3.19%	1,300,954 $19.9 Million
Q2 2024 Aug 14, 2024	BUY	$14.59 - $18.48 $1.6 Million - $2.03 Million	109,654 Added 9.53%	1,260,782 $19.2 Million
Q1 2024 May 14, 2024	SELL	$14.83 - $20.18 $516,321 - $702,586	-34,816 Reduced 2.94%	1,151,128 $21.7 Million
Q4 2023 Feb 14, 2024	BUY	$13.43 - $19.63 $3.38 Million - $4.93 Million	251,361 Added 26.9%	1,185,944 $22.7 Million
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $1.87 Million - $2.49 Million	-105,848 Reduced 10.17%	934,583 $16.8 Million
Q2 2023 Aug 15, 2023	BUY	$16.97 - $22.03 $381,858 - $495,719	22,502 Added 2.21%	1,040,431 $21.1 Million
Q1 2023 May 15, 2023	BUY	$15.96 - $23.15 $2.12 Million - $3.07 Million	132,798 Added 15.0%	1,017,929 $18.6 Million
Q4 2022 Feb 14, 2023	SELL	$19.7 - $35.71 $2.98 Million - $5.41 Million	-151,466 Reduced 14.61%	885,131 $18.3 Million
Q3 2022 Nov 15, 2022	SELL	$23.23 - $30.07 $2.13 Million - $2.76 Million	-91,901 Reduced 8.14%	1,036,597 $27.1 Million
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $1.01 Million - $2.21 Million	58,555 Added 5.47%	1,128,498 $28.6 Million
Q1 2022 May 13, 2022	BUY	$28.92 - $41.83 $29.7 Million - $42.9 Million	1,025,643 Added 2315.22%	1,069,943 $33.8 Million
Q4 2021 Feb 14, 2022	SELL	$31.38 - $48.47 $225,936 - $348,984	-7,200 Reduced 13.98%	44,300 $1.79 Million
Q2 2021 Jul 30, 2021	BUY	$22.75 - $35.77 $147,875 - $232,505	6,500 Added 14.44%	51,500 $1.41 Million
Q1 2021 May 06, 2021	BUY	$26.16 - $41.39 $28,776 - $45,529	1,100 Added 2.51%	45,000 $1.26 Million
Q3 2020 Nov 12, 2020	SELL	$17.14 - $25.47 $113,124 - $168,102	-6,600 Reduced 13.07%	43,900 $752,000
Q2 2020 Aug 13, 2020	BUY	$13.97 - $36.56 $164,846 - $431,408	11,800 Added 30.49%	50,500 $1.25 Million
Q1 2020 May 14, 2020	BUY	$8.78 - $19.28 $71,118 - $156,168	8,100 Added 26.47%	38,700 $537,000
Q4 2019 Feb 18, 2020	BUY	$7.33 - $10.79 $21,257 - $31,290	2,900 Added 10.47%	30,600 $309,000
Q3 2019 Nov 14, 2019	SELL	$6.44 - $10.18 $3,864 - $6,108	-600 Reduced 2.12%	27,700 $252,000
Q2 2019 Aug 14, 2019	BUY	$7.29 - $13.38 $48,114 - $88,308	6,600 Added 30.41%	28,300 $225,000
Q1 2019 May 14, 2019	BUY	$8.95 - $12.49 $97,554 - $136,141	10,900 Added 100.93%	21,700 $271,000
Q4 2018 Feb 13, 2019	BUY	$9.74 - $14.5 $105,192 - $156,600	10,800 New	10,800 $116,000

Others Institutions Holding RCUS

# of Institutions

200

Shares Held

51.5M

Call Options Held

236K

Put Options Held

141K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.15B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Arcus Biosciences, Inc. Transaction History